EP0408294A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Use of an amylin antagonist for the manufacture of amedicament for the treatment of obesity and essential hypertension and related disorders
Assignee: Amylin Pharmaceuticals LLC
•
Filing: 1990-07-10
•
Granted: —
•
Expires: 2010-07-10
Abstract
Abstract The administration of antagonists and blockers of amylin or CGRP or both for the treatment of obesity and essential hypertension and associated lipid disorders and atherosclerosis.
Inventors
- 👤 Garth J.S. Cooper
- 👤 Brendan Leighton
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-28 11:38
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/22; A61K38/225; A61P; A61P3/00; A61P3/06; A61P3/08; A61P9/00; A61P9/10; A61P9/12; C; C07; C07K; C07K16/00; C07K16/18; C07K16/26
Claims Analysis
Total Claims: 20
Claim 1
Independent Claim
26 words
An amylin antagonist for use in a method of treatment of the human or animal body for decreasing basal and submaximally stimulated rates of glycogen synthesis.
Claim 2
Dependent Claim
26 words
An amylin antagonist for use in a method of treatment of the human or animal body for decreasing basal and submaximally stimulated rates of glycogen synthesis.
Claim 3
Dependent Claim
25 words
An amylin antagonist for use in a method of treatment of the human or animal body for the treatment of mammalian obesity and symptoms thereof.
Claim 4
Dependent Claim
25 words
An amylin antagonist for use in a method of treatment of the human or animal body for the treatment of mammalian obesity and symptoms thereof.
Claim 5
Dependent Claim
29 words
An amylin antagonist for use in a method of treatment of the human or animal body for decreasing the rate of incorporation of glucose into glycogen in mammalian muscle.
Claim 6
Dependent Claim
29 words
An amylin antagonist for use in a method of treatment of the human or animal body for decreasing the rate of incorporation of glucose into glycogen in mammalian muscle.
Claim 7
Dependent Claim
28 words
An amylin antagonist for use in a method of treatment of the human or animal body for the treatment of essential hypertension and symptoms thereof in a mammal.
Claim 8
Dependent Claim
28 words
An amylin antagonist for use in a method of treatment of the human or animal body for the treatment of essential hypertension and symptoms thereof in a mammal.
Claim 9
Dependent Claim
15 words
An amylin antagonist according to any one of the preceding claims which is deamidated amylin.
Claim 10
Dependent Claim
16 words
An amylin antagonist according to any one of claims 1 to 4 which is reduced amylin.
Claim 11
Dependent Claim
20 words
An amylin antagonist according to any one of claims 1 to 4 which is a biologically subactive subpeptide of amylin.
Claim 12
Dependent Claim
16 words
An amylin antagonist according to claim 7 wherein said amylin subpeptide is Ser² Ser⁷ amylin 1-16.
Claim 13
Dependent Claim
14 words
An amylin antagonist according to claim 7 wherein said amylin subpreptide comprises amylin 8-37.
Claim 14
Dependent Claim
17 words
An amylin antagonist according to any one of claims 1 to 4 which is a substituted amylin.
Claim 15
Dependent Claim
15 words
An amylin antagonist according to claim 10 wherein said substituted amylin is Ser² Ser⁷ amylin.
Claim 16
Dependent Claim
17 words
An amylin antagonist according to any one of claims 1 to 4 which is derived from CGRP.
Claim 17
Dependent Claim
18 words
An amylin antagonist accoring to any one of claims 1 to 4 which comprises an anti-amylin receptor antibody.
Claim 18
Dependent Claim
17 words
An amylin antagonist according to any one of claims 1 to 4 which comprises an anti-amylin antibody.
Claim 19
Dependent Claim
56 words
The use of an amylin antagonist in the manufacture of a medicament for decreasing basal and submaximally stimulated rates of glycogen synthesis, or for the treatment of mammalian obesity and symptoms thereof, or for decreasing the rate of incorporation of glucose into glycogen in mammalian muscle or for the treatment of essential hypertension and symptoms thereof.
Claim 20
Dependent Claim
56 words
The use of an amylin antagonist in the manufacture of a medicament for decreasing basal and submaximally stimulated rates of glycogen synthesis, or for the treatment of mammalian obesity and symptoms thereof, or for decreasing the rate of incorporation of glucose into glycogen in mammalian muscle or for the treatment of essential hypertension and symptoms thereof.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.